X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
index medicus (16) 16
oncology (16) 16
female (14) 14
middle aged (11) 11
adult (10) 10
breast cancer (9) 9
aged (8) 8
breast neoplasms - pathology (6) 6
male (6) 6
cancer (5) 5
chemotherapy (5) 5
aged, 80 and over (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cancer therapies (4) 4
mutation (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
breast neoplasms - genetics (3) 3
carcinoma (3) 3
follow-up studies (3) 3
germline mutations (3) 3
jews (3) 3
liver neoplasms - secondary (3) 3
ovarian cancer (3) 3
receptor, erbb-2 - metabolism (3) 3
survival (3) 3
survival analysis (3) 3
treatment outcome (3) 3
tumors (3) 3
5-fluorouracil (2) 2
adjuvant chemotherapy (2) 2
age (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
article (2) 2
bone neoplasms - secondary (2) 2
breast (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - metabolism (2) 2
breast neoplasms - mortality (2) 2
breast neoplasms - therapy (2) 2
breast-cancer (2) 2
cell differentiation - drug effects (2) 2
cisplatin - administration & dosage (2) 2
combination (2) 2
disease-free survival (2) 2
endocrine therapy (2) 2
estrogen (2) 2
fluorouracil - administration & dosage (2) 2
fluorouracil - adverse effects (2) 2
genetic research (2) 2
germ-line mutation - genetics (2) 2
health aspects (2) 2
history (2) 2
israel (2) 2
kaplan-meier estimate (2) 2
leucovorin - administration & dosage (2) 2
liver neoplasms - drug therapy (2) 2
lymph nodes - pathology (2) 2
lymphatic metastasis (2) 2
mastectomy (2) 2
medicine & public health (2) 2
medicine, general & internal (2) 2
mutations (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
neuregulins (2) 2
oral uft (2) 2
ovarian neoplasms - genetics (2) 2
paclitaxel (2) 2
phenols (2) 2
progression-free survival (2) 2
prospective studies (2) 2
proto-oncogene proteins - biosynthesis (2) 2
radiation therapy (2) 2
receptor, epidermal growth factor - biosynthesis (2) 2
receptors, estrogen - metabolism (2) 2
retrospective studies (2) 2
risk (2) 2
tamoxifen (2) 2
tegafur (2) 2
tegafur - administration & dosage (2) 2
trial (2) 2
tumor cells, cultured (2) 2
uracil - administration & dosage (2) 2
women (2) 2
womens health (2) 2
1st-line treatment (1) 1
abridged index medicus (1) 1
adenocarcinoma (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
adenosine (1) 1
adenosine diphosphate (1) 1
adolescent (1) 1
advanced breast cancer (1) 1
advanced colorectal-cancer (1) 1
advanced esophagogastric cancer (1) 1
anemia - chemically induced (1) 1
anemia - epidemiology (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 22, pp. 2154 - 2164
Among patients with platinum-sensitive, recurrent ovarian cancer, the use of niraparib, a PARP inhibitor, was associated with a significantly longer duration... 
TRIAL | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | BRCA MUTATION CARRIERS | NEGATIVE BREAST-CANCER | Humans | Middle Aged | Homologous Recombination | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Germ-Line Mutation | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Bone Marrow - drug effects | Double-Blind Method | Kaplan-Meier Estimate | Disease-Free Survival | Piperidines - therapeutic use | Piperidines - adverse effects | Adolescent | Aged | Indazoles - adverse effects | Neoplasm Staging | Indazoles - therapeutic use | Care and treatment | Adenosine diphosphate | Research | Diagnosis | Patients | Health aspects | Ovarian cancer | Thrombocytopenia | Adenosine | Inhibitor drugs | Toxicity | Homologous recombination | Clinical trials | Poly(ADP-ribose) polymerase | Breast cancer | Cancer therapies | Survival | Ribose | Platinum | Bone marrow | Mutation | Drug therapy | Health risk assessment | Tumors | Neutropenia | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Obstetrical & Gynecological Survey, ISSN 0029-7828, 02/2017, Volume 72, Issue 2, pp. 91 - 92
(Abstracted from N Engl J Med 2016;375(22):2154–2164)The initial response rate to platinum and taxane treatment in patients with advanced ovarian cancer is... 
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 04/2018, Volume 18, Issue 2, pp. e197 - e203
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 766 - 773
Pertuzumab combined with trastuzumab and docetaxel is the standard first-line therapy for HER2-positive metastatic breast cancer, based on results from the... 
paclitaxel | first line | pertuzumab | dual HER2 blockade | HER2-positive | metastatic breast cancer | WEEKLY PACLITAXEL | ONCOLOGY | NAB-PACLITAXEL | PROGRESSION-FREE SURVIVAL | DOCETAXEL
Journal Article
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e12053 - e12053
Conference Proceeding
Journal Article
NPJ breast cancer, ISSN 2374-4677, 2017, Volume 3, Issue 1, pp. 32 - 7
The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry... 
Lymphatic system | Chemotherapy | Breast cancer | Gene expression | Cancer therapies
Journal Article
Chemotherapy, ISSN 0009-3157, 02/2009, Volume 55, Issue 2, pp. 76 - 82
Background: Compared with systemic therapy, hepatic arterial infusion (HAI) increases the response to fluoropyrimidines. Methods: Thirty-one patients with... 
Clinical Study | Hepatic arterial infusion | Irinotecan | Liver metastases | UFT | 5-Fluorouracil | Tegafur | Colorectal cancer | Leucovorin | Uracil | 1ST-LINE TREATMENT | DIHYDROPYRIMIDINE DEHYDROGENASE | RESECTION | THYMIDYLATE SYNTHASE EXPRESSION | FLUOROURACIL | COMBINATION | TUMORS | FLUOROPYRIMIDINE-BASED CHEMOTHERAPY | ORAL UFT | ONCOLOGY | PROTEIN EXPRESSION | PHARMACOLOGY & PHARMACY | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Liver Neoplasms - mortality | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Uracil - administration & dosage | Fluorouracil - adverse effects | Dihydrouracil Dehydrogenase (NADP) - analysis | Adult | Camptothecin - administration & dosage | Female | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Tegafur - adverse effects | Hepatic Artery | Liver Neoplasms - drug therapy | Uracil - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Colorectal Neoplasms - pathology | Infusions, Intra-Arterial | Chemotherapy | Drug delivery systems | Colon | Metastasis | Liver | Cancer | Index Medicus
Journal Article
NPJ breast cancer, ISSN 2374-4677, 2017, Volume 3, Issue 1, pp. 33 - 8
The 21-gene Recurrence Score® (RS) assay is a validated prognostic/predictive tool in ER + early-stage breast cancer. However, clinical outcome data from... 
Chemotherapy | Womens health | Endocrine therapy | Mammography | Breast cancer | Cancer therapies | Clinical outcomes
Journal Article
Journal Article
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 11/1993, Volume 53, Issue 21, pp. 5251 - 5261
Journal Article